Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Gross Margin (2016 - 2025)

Historic Gross Margin for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to 51.48%.

  • Integra Lifesciences Holdings' Gross Margin fell 11000.0% to 51.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 52.33%, marking a year-over-year decrease of 25900.0%. This contributed to the annual value of 54.77% for FY2024, which is 26200.0% down from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Gross Margin is 51.48%, which was down 11000.0% from 50.37% recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Gross Margin peaked at 62.83% during Q4 2022, and registered a low of 50.37% during Q2 2025.
  • For the 5-year period, Integra Lifesciences Holdings' Gross Margin averaged around 57.64%, with its median value being 57.1% (2023).
  • Per our database at Business Quant, Integra Lifesciences Holdings' Gross Margin soared by 26500bps in 2022 and then plummeted by -84000bps in 2023.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Gross Margin stood at 61.47% in 2021, then rose by 2bps to 62.83% in 2022, then decreased by -9bps to 57.05% in 2023, then fell by -1bps to 56.27% in 2024, then dropped by -9bps to 51.48% in 2025.
  • Its last three reported values are 51.48% in Q3 2025, 50.37% for Q2 2025, and 50.81% during Q1 2025.